Condition

Primary Hypercholesterolemia

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7
Recruiting0
Common interventions21
Lead sponsors shown3
Advertisement

Clinical trials

7 shown
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.NCT07685054 · 2026-08-01
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult VolunteersNCT06889012 · 2025-05-07
COMPLETED
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018CNCT06165250 · 2024-04-17
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"NCT06184269 · 2023-12-23
COMPLETED
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaNCT05930028 · 2023-07-13
COMPLETED
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022NCT06448962 · 2020-10-22
COMPLETED
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary HypercholesterolemiaNCT04659070 · 2020-07-15
UNKNOWN

Trial status mix

COMPLETED5
NOT_YET_RECRUITING1
UNKNOWN1

Phase mix

PHASE34
PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.